| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
25,980,000 |
| Market
Cap: |
126.26(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.11 - $38 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
200 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,250 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
231,724 |
319,059 |
891,005 |
891,005 |
| Total Sell Value |
$811,485 |
$1,915,016 |
$14,925,115 |
$14,925,115 |
| Total People Sold |
1 |
4 |
11 |
11 |
| Total Sell Transactions |
13 |
17 |
57 |
57 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-10-10 |
4 |
AS |
$21.94 |
$114,462 |
D/D |
(5,200) |
106,135 |
|
-66% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-10-10 |
4 |
OE |
$6.00 |
$31,200 |
D/D |
5,200 |
111,335 |
|
- |
|
| Szalay Aladar |
10% Owner |
– – • |
2023-10-05 |
4 |
S |
$24.89 |
$355,229 |
I/I |
(14,251) |
1,427,236 |
|
67% |
|
| Szalay Aladar |
10% Owner |
– – • |
2023-10-03 |
4 |
S |
$25.49 |
$1,929,225 |
I/I |
(75,690) |
1,441,487 |
|
65% |
|
| Szalay Aladar |
10% Owner |
– – • |
2023-09-28 |
4 |
S |
$24.12 |
$55,211 |
I/I |
(2,289) |
1,517,177 |
|
65% |
|
| Szalay Aladar |
10% Owner |
– – • |
2023-09-27 |
4 |
S |
$24.47 |
$275,459 |
I/I |
(11,257) |
1,519,466 |
|
65% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-09-26 |
4 |
AS |
$22.54 |
$122,528 |
D/D |
(5,200) |
106,135 |
|
-62% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-09-26 |
4 |
OE |
$6.00 |
$31,200 |
D/D |
5,200 |
111,335 |
|
- |
|
| Szalay Aladar |
10% Owner |
– – • |
2023-09-26 |
4 |
S |
$22.47 |
$709,177 |
I/I |
(29,805) |
1,530,723 |
|
62% |
|
| Szalay Aladar |
10% Owner |
– – • |
2023-09-25 |
4 |
S |
$24.82 |
$321,004 |
I/I |
(12,458) |
1,560,528 |
|
61% |
|
| Szalay Aladar |
10% Owner |
– – • |
2023-09-22 |
4 |
S |
$26.88 |
$247,123 |
I/I |
(9,042) |
1,572,986 |
|
61% |
|
| Szalay Aladar |
10% Owner |
– – • |
2023-09-21 |
4 |
S |
$27.89 |
$214,878 |
I/I |
(7,549) |
1,582,028 |
|
62% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-09-20 |
4 |
AS |
$27.96 |
$167,786 |
D/D |
(6,000) |
106,135 |
|
-62% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-09-20 |
4 |
OE |
$6.00 |
$36,000 |
D/D |
6,000 |
112,135 |
|
- |
|
| Ryder Sean |
General Counsel |
• – – |
2023-09-20 |
4 |
AS |
$30.00 |
$300,000 |
D/D |
(10,000) |
572 |
|
-62% |
|
| Ryder Sean |
General Counsel |
• – – |
2023-09-20 |
4 |
OE |
$6.00 |
$60,000 |
D/D |
10,000 |
10,572 |
|
- |
|
| Szalay Aladar |
10% Owner |
– – • |
2023-09-19 |
4 |
S |
$26.21 |
$850,942 |
D/D |
(32,167) |
0 |
|
60% |
|
| Szalay Aladar |
10% Owner |
– – • |
2023-09-18 |
4 |
S |
$23.20 |
$705,649 |
I/I |
(30,292) |
5,000 |
|
60% |
|
| Thomas John |
Director |
– • – |
2023-09-18 |
4 |
AS |
$24.99 |
$83,317 |
D/D |
(3,334) |
475,793 |
|
-60% |
|
| Thomas John |
Director |
– • – |
2023-09-15 |
4 |
AS |
$21.67 |
$72,996 |
D/D |
(3,333) |
479,127 |
|
-52% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-09-15 |
4 |
AS |
$21.56 |
$227,630 |
D/D |
(10,400) |
106,135 |
|
-52% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-09-15 |
4 |
OE |
$6.00 |
$62,400 |
D/D |
10,400 |
116,535 |
|
- |
|
| Szalay Aladar |
10% Owner |
– – • |
2023-09-14 |
4 |
S |
$21.77 |
$557,806 |
I/I |
(25,276) |
35,292 |
|
52% |
|
| Yu Tony |
VP, Clinical Trial Operations |
• – – |
2023-09-13 |
4 |
S |
$21.14 |
$629,927 |
D/D |
(29,800) |
106,135 |
|
46% |
|
| Szalay Aladar |
10% Owner |
– – • |
2023-09-13 |
4 |
S |
$21.26 |
$408,093 |
I/I |
(19,032) |
60,568 |
|
46% |
|
91 Records found
|
|
Page 2 of 4 |
|
|
0.16 (3.19%) 
